Diligence memo · auto-generated · as of July 2, 2026
Cingulate Therapeutics
Cingulate Therapeutics looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Cingulate Therapeutics operates in Pharmaceuticals, based in Kansas City.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cingulate Therapeutics has raised $33M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $26M on 2013-11-14.
Most recent recorded round closed around 2013-11-14.
Valuation (modeled)modeled
Provath models Cingulate Therapeutics at approximately $891M (range $55M–$3.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.31× the median modeled value of Series B Pharmaceuticals companies in 2013–2015 (42 peers) — value vs value, same stage and era. Within the normal band (131% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 12.6 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 6.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 75% of Pharmaceuticals peers (1610 compared).
Modeled value ranks above 87% of those peers.
Closest niche peers: Lipocine Inc., CARDEAS PHARMA Corp, CoLucid Pharmaceuticals, Inc., Emisphere Technologies Inc, Vasculox, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.